Oncotelic Therapeutics, Inc. (OTLC) Operating income 2017–2025
Oncotelic Therapeutics, Inc. (OTLC) annual operating income history from SEC filings — each fiscal year as reported.
-$3.2MFY2025 · since FY2017: -$13.8M → -$3.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$3.2M | +10.9% |
| FY2024 | -$3.6M | +46.2% |
| FY2023 | -$6.6M | +31.6% |
| FY2022 | -$9.7M | -6.5% |
| FY2021 | -$9.1M | -20.3% |
| FY2020 | -$7.6M | -75.9% |
| FY2019 | -$4.3M | -504.8% |
| FY2018 | -$712,738 | +94.9% |
| FY2017 | -$13.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More OTLC financial trends
OTLC RevenueOTLC Net incomeOTLC Net marginOTLC Gross profitOTLC Gross marginOTLC Operating marginOTLC Operating cash flowOTLC Free cash flowOTLC Capital expendituresOTLC Return on equityOTLC Stock buybacksOTLC Dividends paidOTLC Total assetsOTLC Total liabilitiesOTLC Shareholders’ equityOTLC overview →